SequelSEC

Protara Therapeutics, Inc. TARA

Biological Products, (No Diagnostic Substances) · CIK 0001359931 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.95M
Fiscal year ended 2014-12-31
Operating income
-$7.58M
Fiscal year ended 2014-12-31
Free cash flow
Unavailable
Fiscal year ended 2014-12-31

Protara Therapeutics, Inc. (TARA) reported revenue of $2.95M and net income of -$3.34M for the fiscal year ended 2014-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Protara Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Protara Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2014-12-31
Revenue$2.95M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$7.58M
Net income-$3.34M
Research & development$6.43M
Weighted-average diluted sharesUnavailable
Pretax income-$3.34M
Income tax expense-$110.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$4.10M
Selling & marketingUnavailable

Balance

Protara Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2014-12-31
Cash & equivalents$68.84M
Total assets$84.80M
Current assets$84.60M
Total liabilities$2.34M
Current liabilities$2.34M
Total equity incl. NCI$82.46M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$917.00K

Cash flow

Protara Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2014-12-31
Operating cash flowUnavailable
Capital expenditures$51.00K
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cash$66.05M
Stock-based compensation$459.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$30.00K

Derived

Protara Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2014-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-257.1%
FCF marginUnavailable
SBC / revenue15.6%
Current ratio36.19x
Revenue YoY growthUnavailable
Net margin-113.4%
R&D / revenue218.2%
CapEx / revenue1.7%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TARA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.